New center will support development of new therapeutics, which bodes well for celiac treatment research.
The National Institutes of Health (NIH) has announced plans to create a new center that will focus on developing new therapeutics and making the transition from laboratory to bedside faster. For individuals with celiac disease and other illnesses, this could mean new treatments and therapies will be on the way sooner.
The announcement was made on Dec. 8, 2010, after a senior working group approved the new center for Translational Medicine and Therapeutics (TMAT). The center will assume several duties, such as fostering research in diagnostics and therapeutics and streamlining the development process so discoveries can move out of the lab and into practice. The TMAT center will also manage some of the NIH’s clinical and development awards programs and grants, and will take over the agency’s partnership with the Food and Drug Administration. Collaborations between the NIH and the external research community, academia, private sector and government will prove to be important components of the TMAT Center.
NIH Director Francis Collins plans to take quick action and have the center funded by fiscal year 2012, GenomeWeb News reported.
“Because efforts to translate discoveries and research into medicine face many challenges, Collins explained, ‘Gradual evolution is not adequate to meet these challenges,’” the article stated.
To learn more about this announcement, read the report from GenomeWeb News.
NFCA Founder & President Alice Bast recently attended the Development of Therapies for Celiac Disease Conference in New York City. NFCA Healthcare Relations Manager Kristin Voorhees, who also attended the conference, reported the top 6 highlights in NFCA’s December 2010 newsletter.